The US government transferred 833.6 BTC worth over $71 million from wallets linked to the 2016 Bitfinex hack and the Potapenko-Turogin fraud case, marking its first bitcoin movement since August 26. The coins were moved to Coinbase Prime, which manages digital assets for the US Marshals Service, indicating a shift from auction sales to direct custody handling. Alongside Bitcoin, $31.63 million worth of BNB from forfeited FTX wallets was also moved. Despite these transfers, the government still holds a massive stash of 323,693.83 BTC valued at around $27.72 billion.
The US government’s recent $71 million Bitcoin transfer offers context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Oct 07, 2026 05:52 WIB: out of 50 major cryptocurrencies, 8 rose and 41 fell today. Notable movers include CAKE at Rp42.894 with a 4.30% decline and a typical hold time of 75 days, EGLD at Rp79.645 down 4.07%, and ZIL at Rp63 down 3.93%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
